Author

Diego S. Fajardo

University of Florida

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Shannon E. BoyeiD· 2 shared Antonia Fottner· 1 shared Christian GrimmiD· 1 shared Christopher Kozlowski· 1 shared Claudia Matter· 1 shared Cornelia Imsand· 1 shared Duygu KarademiriD· 1 shared Emily M. XuiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Shannon E. BoyeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Preclinical Development and Safety of Laterally Spreading Dual AAV.SPR-MYO7A Vectors for the Treatment of Usher Syndrome Type 1B

Kaitlyn R. Calabro, Eva Andrés‐Mateos, Christopher Kozlowski, Paige S. Nemec, Emily M. Xu, Sean M. Crosson, Diego S. Fajardo, Hannah L. Friend, James J. Peterson, Wei Li, Hangning Zhang, Hugh Lee Sweeney, Victoria A. Stevenson, Howard Rind, Matthew Leahy, , Shannon E. Boye

This paper develops and tests dual AAV vectors for treating USH1B by reconstituting full-length MYO7A expression, showing safety and efficacy in non-human primates.

bioRxiv · Oct 29, 2026 · PreprintGenetics

A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD

Lynn J. A. Ebner, Cornelia Imsand, Duygu Karademir, Florian Peters, Eva Kiessling, Antonia Fottner, Claudia Matter, Diego S. Fajardo, Luca Merolla, Gabriele M Wögenstein, Ioanna Tsioti, Larissa P. Govers, Frank Blaser, Isabelle Meneau, Sanford L. Boye, , Marijana Samardzija

This paper develops a dual-acting RNAi therapy targeting Hif1a and Hif2a to protect retinal cells in AMD models, showing superior efficacy compared to single-target therapies.

Molecular Therapy · Sep 27, 2025Peer-reviewedNeuroscience